Experimental HCV Drugs
Experimental HCV Drugs
TAG Offers New Guide to Clinical Trials for People with Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 17 August 2011 00:00
- Written by Liz Highleyman
The Treatment Action Group (TAG) has produced a new booklet for people considering taking part in clinical trials for new therapies for hepatitis C.
4-Drug Regimen Can Cure Genotype 1 Hepatitis C in 12 Weeks
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 02 August 2011 00:00
- Written by Vertex Pharmaceuticals
Interim results from the Phase 2 ZENITH study show that previously untreated people with HCV genotype 1 can achieve sustained response in as little as 12 weeks using a quadruple regimen consisting of telaprevir (Incivek), the experimental HCV polymerase inhibitor VX-222, pegylated interferon, and ribavirin. A newly added arm will evaluate telaprevir, VX-222, and ribavirin without interferon. 
PSI-7977 plus Standard Therapy Cures 100% of Genotype 2-3 Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 26 July 2011 00:00
- Written by Pharmasset
Pharmasset's investigational hepatitis C virus (HCV) polymerase inhibitor PSI-7977 combined with pegylated interferon/ribavirin cured 100% of people with HCV genotype 2 and 3 in the Phase 2b PROTON trial; sustained response results for hard-to-treat genotype 1 patients are expected later this year.
Pipeline Report Shows Good Prospects for People with HIV, HCV, and TB
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 29 July 2011 00:00
- Written by TAG & iBase
An updated summary of experimental therapies for HIV, hepatitis C virus (HCV), and tuberculosis, produced by treatment advocates with i-Base and TAG, shows rapid progress in therapies for HCV and steady progress in the area of HIV.
TMC435 for HCV Gets Fast Tracked, Studied with PSI-7977
- Details
- Category: Hepatitis C
- Published on Tuesday, 12 July 2011 00:00
- Written by Liz Highleyman
The HCV NS3/4A protease inhibitor TMC435 was recently given FDA Fast Track status for expedited approval; it will be studied in an all-oral regimen with the HCV polymerase inhibitor PSI-7977.
Web Design and Development by